Breaking News Instant updates and real-time market news.

RDUS

Radius Health

$27.41

0.71 (2.66%)

18:34
12/07/17
12/07
18:34
12/07/17
18:34

Radius Healths says elacestrant still 'shows promise' in advanced breast cancer

Radius Health provided an update on data from the Phase 1 005 clinical study of elacestrant, an oral selective estrogen receptor degrader, in patients with estrogen receptor positive breast cancer. The data were presented at a Spotlight Presentation during the 2017 San Antonio Breast Cancer Symposium. Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration. There are 40 patients that have been treated at the 400 mg dose in the elacestrant Phase I dose escalation and expansion cohorts. All study participants are heavily pretreated ER+, HER2-negative, advanced breast cancer patients that have received a median of three prior lines of systemic therapy and have evaluable advanced or metastatic disease. Of the enrolled patients, 22 patients met the RECIST measurable disease criteria at baseline and there were 6 confirmed partial responses in this group. Elacestrant was well-tolerated with the most common adverse events being low grade nausea, dyspepsia and vomiting. "It is quite encouraging to see the clinical activity with elacestrant in the heavily pretreated advanced patient population, and further therapeutic development is warranted for patients with hormone receptor positive breast cancer", commented Dr. Aditya Bardia, Director of Precision Medicine and attending physician at Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.

RDUS Radius Health
$27.41

0.71 (2.66%)

05/22/17
JPMS
05/22/17
NO CHANGE
Target $74
JPMS
Overweight
Amgen data a 'clear positive' for Radius Health, says JPMorgan
JPMorgan analyst Jessica Fye believes the imbalance in observed cardiovascular serious adverse events reported by Amgen (AMGN) and UCB over the weekend for Evenity is a "clear positive" for Radius Health (RDUS). The FDA will now add results from the Phase 3 ARCH study to the regulatory review, and as a result Amgen does not expect U.S. approval for Evenity in 2017, Fye tells investors in a research note. The update is a "clear positive" for Radius Health, who has Tymlos already approved with a clean clinical safety profile, the analyst contends. She continues to believe Tymlos is well positioned for a successful launch into the large market opportunity of postmenopausal women with osteoporosis at high risk of fracture. Fye has an Overweight rating on Radius with a $74 price target. The stock in premarket trading is up 13%, or $4.62, to $39.55.
05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
12/06/17
SBSH
12/06/17
INITIATION
Target $30
SBSH
Neutral
Radius Health initiated with a Neutral at Citi
Citi analyst Robyn Karnauskas started Radius Health with a Neutral rating and $30 price target. The analyst believes the Tymlos launch will be the key story for 2018 and prefers to wait on the sidelines until the company's cancer program comes to the forefront.

TODAY'S FREE FLY STORIES

WEN

Wendy's

$15.63

0.24 (1.56%)

, MCD

McDonald's

$173.35

-0.2 (-0.12%)

15:41
12/14/17
12/14
15:41
12/14/17
15:41
Hot Stocks
Chanos says he'd short almost all fast food stocks, except McDonald's »

While being interviewed…

WEN

Wendy's

$15.63

0.24 (1.56%)

MCD

McDonald's

$173.35

-0.2 (-0.12%)

QSR

Restaurant Brands

$61.49

0.16 (0.26%)

YUM

Yum! Brands

$82.12

-0.07 (-0.09%)

JACK

Jack in the Box

$102.49

-0.09 (-0.09%)

SONC

Sonic

$28.32

0.38 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

SLM

Sallie Mae

$11.16

-0.45 (-3.88%)

15:40
12/14/17
12/14
15:40
12/14/17
15:40
Options
Sallie Mae sees notable call buying »

Sallie Mae sees notable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$39.53

0.24 (0.61%)

, PRGO

Perrigo

$82.91

-3.11 (-3.62%)

15:36
12/14/17
12/14
15:36
12/14/17
15:36
Periodicals
Mylan, Perrigo among those interesed in Merck KGaA unit, Bloomberg says »

Mylan (MYL), Perrigo…

MYL

Mylan

$39.53

0.24 (0.61%)

PRGO

Perrigo

$82.91

-3.11 (-3.62%)

MKGAY

Merck KGaA

RBGLY

Reckitt Benckiser

$18.17

0.11 (0.61%)

NSRGY

Nestle

$86.67

0.61 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$26.16

0.62 (2.43%)

15:34
12/14/17
12/14
15:34
12/14/17
15:34
Periodicals
Airbus COO expected to step down, Reuters reports »

Airbus COO and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBL

Jabil Circuit

$27.56

-0.99 (-3.47%)

15:34
12/14/17
12/14
15:34
12/14/17
15:34
Options
Jabil Circuit options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 09

    Jan

MCD

McDonald's

$173.34

-0.21 (-0.12%)

, QSR

Restaurant Brands

$61.42

0.09 (0.15%)

15:32
12/14/17
12/14
15:32
12/14/17
15:32
Hot Stocks
Jim Chanos says not short McDonald's, but is short other fast food stocks »

Chanos, in making…

MCD

McDonald's

$173.34

-0.21 (-0.12%)

QSR

Restaurant Brands

$61.42

0.09 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPR

Express

$10.30

-0.66 (-6.02%)

15:30
12/14/17
12/14
15:30
12/14/17
15:30
Options
Express calls active as shares see relative weakness »

Express calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

, DIS

Disney

$111.17

3.555 (3.30%)

15:29
12/14/17
12/14
15:29
12/14/17
15:29
Recommendations
21st Century Fox, Disney analyst commentary  »

21st Century Fox should…

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

DIS

Disney

$111.17

3.555 (3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 15

    Dec

TSLA

Tesla

$339.03

-2 (-0.59%)

15:28
12/14/17
12/14
15:28
12/14/17
15:28
Hot Stocks
Tesla 'already behind' on vehicle autonomy, Chanos says »

Jim Chanos of Kynikos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$339.03

-2 (-0.59%)

15:27
12/14/17
12/14
15:27
12/14/17
15:27
Hot Stocks
Chanos says Tesla CEO Musk 'has broad interpretation of truth' »

Jim Chanos, who is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

BTC

Bitcoin

, BITCOIN

Bitcoin

15:19
12/14/17
12/14
15:19
12/14/17
15:19
General news
Chanos says 'not short' bitcoin but 'speculation' in it indicative of market »

Jim Chanos of Kynikos…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$176.83

4.29 (2.49%)

15:19
12/14/17
12/14
15:19
12/14/17
15:19
Options
Adobe options imply 6.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

EADSY

Airbus

$26.16

0.62 (2.43%)

15:17
12/14/17
12/14
15:17
12/14/17
15:17
Periodicals
Breaking Periodicals news story on Airbus »

Airbus CEO intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
12/14/17
12/14
15:17
12/14/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$23.11

-0.75 (-3.14%)

, ESRX

Express Scripts

$68.57

0.01 (0.01%)

15:16
12/14/17
12/14
15:16
12/14/17
15:16
Periodicals
Chanos says tax bill will affect healthcare more than people think »

Chanos mentioned…

MNK

Mallinckrodt

$23.11

-0.75 (-3.14%)

ESRX

Express Scripts

$68.57

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

$NYE

NYSE Market Internals

15:16
12/14/17
12/14
15:16
12/14/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$266.05

-0.705 (-0.26%)

15:12
12/14/17
12/14
15:12
12/14/17
15:12
Periodicals
Speaker Ryan says not leaving Congress anytime soon, CBS News reports »

Following a media report…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$266.05

-0.705 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$2.93

-0.095 (-3.15%)

15:10
12/14/17
12/14
15:10
12/14/17
15:10
Options
Bulls and bears in JC Penney Thursday »

Bulls and bears in JC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

, CMCSK

Comcast

15:06
12/14/17
12/14
15:06
12/14/17
15:06
Periodicals
Comcast offered more for Fox assets, but Fox preffered Disney deal, CNBC says »

Sources tell CNBC's…

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

CMCSK

Comcast

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

FOX

21st Century Fox

$32.34

-1.26 (-3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

COST

Costco

$188.28

-0.02 (-0.01%)

15:04
12/14/17
12/14
15:04
12/14/17
15:04
Options
Costco options imply 5.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

VRX

Valeant

$19.22

-2.83 (-12.83%)

15:03
12/14/17
12/14
15:03
12/14/17
15:03
Technical Analysis
Technical View: Valeant near session lows, levels to watch »

The shares are bouncing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 27

    Dec

  • 18

    Jun

CI

Cigna

$204.17

-3.75 (-1.80%)

15:02
12/14/17
12/14
15:02
12/14/17
15:02
Hot Stocks
Cigna announces acquisition of digital health plan platform Brighter »

Cigna announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/14/17
12/14
15:00
12/14/17
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

ORCL

Oracle

$50.25

0.195 (0.39%)

14:49
12/14/17
12/14
14:49
12/14/17
14:49
Options
Oracle options imply 7.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DIS

Disney

$111.04

3.43 (3.19%)

, FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

14:44
12/14/17
12/14
14:44
12/14/17
14:44
Recommendations
Disney, 21st Century Fox analyst commentary  »

RBC Capital sees Disney,…

DIS

Disney

$111.04

3.43 (3.19%)

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 15

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.